

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
1 April 2004 (01.04.2004)

PCT

(10) International Publication Number
WO 2004/026895 A2

(51) International Patent Classification⁷: **C07K 7/04**,
7/64, A61K 38/04

H3G 1Y6 (CA). SARAGOVI, H., Uri [US/CA]; McGill University, Pharmacology and Therapeutics, 3655 Drummond St., #1320, Montreal, Québec H3G 1Y6 (CA).

(21) International Application Number:
PCT/CA2003/001389

(74) Agent: SMART & BIGGAR; Attn. : Kingwell, Brian, G., Box 11560, Vancouver Centre, 2200 - 650 West Georgia Street, Vancouver, British Columbia V6B 4N8 (CA).

(22) International Filing Date:
19 September 2003 (19.09.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/412,492 20 September 2002 (20.09.2002) US

(71) Applicant (for all designated States except US): MCGILL UNIVERSITY [CA/CA]; Office of Technology Transfer, 3550 University Street, Montreal, Québec H3A 2A7 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT (utility model), AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK (utility model), SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(72) Inventors; and

(75) Inventors/Applicants (for US only): GAGNON, Martin [CA/CA]; McGill University, Pharmacology and Therapeutics, 3655 Drummond St., #1320, Montreal, Québec

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,

[Continued on next page]

(54) Title: GD2 LIGANDS

mgadgetvvl knmliginli llgsmikpse cqlvttterv grqsvvee **gg ianynts** ske 61
qpvvfnhvyn invpldnlcs sgleasaeqe vsaedetlae ymgqtsdhes qvtfthrinf 121
pkkacpcass aqvlqellsr iemlerevsv lrdqcnancc qesaatgqld yiphcsghgn 181
fsfescgcic negwfgkncs epycplgcss rgvcvdgqci cdseysgddc selrcptdcs 241
srglcvdgec vceepytged crelrcpgdc sgkgrcangt clceegyvgc dcgqrqclna 301
csgrgqceeg lcvceegyqg pdcsavappe dlrvagisdr sielewdgpm avteyvisyq 361
ptalgglqlq qrvpgdwsqv titelepglt ynisyvavis nilslpitak vathlstpqg 421
lqfktitett vevqwepfsf sfdgweisfi pknneggvia qvpsdvtsfn qtglkpgeey 481
ivnvvalkeq arspptsasv stvidgptqi lvrdsdvtva fvewipprak vdfillkygl 541
vggeggrttf rlqpplsqsy vqalrpgsry evsvsavgtr nesdsattqf tteidapkn 601
rvgsrtatsl dlewdnseae vqeykvyst lageqyhevl vprgigpttr atldtlvpqt 661
eygvgisavm nsqqsypatm narteldspr dlmvtasset sisliwtkas gpidthyritf 721
tpssgiasev tvpkdrtsyt ltdlepgaey iisvtaergr qqslestvda ftgfrpishl 781
hfshvtsssv nitwsdpssp adrlilnysp rdeeeemnev sldatkrhav lmglqpatey 841
ivnlvavhgt vtsepivgst ttgidppkdi tsnvtdkdv mvswsppvas fdyyrvsy 901
tqvgrldssv vpntvtefti trlnpateye islnsvrgre eserictlvh tamdnvpdli 961
atnitptcal lqwkavpgev enyviwlthf avagetilvd gvseefrlvd llpsthyyat 1021
myatngplts gtistnfstl ldppanltas evtrqsalis wqppraeien yvltystdg 1081
srkelivdae dtwirlegll entdytvllq aaqdtwssi tstafttgr vfpqhdaq 1141
hlmgdtlsg vvpiflmgel sqklqvycdm ttdgggwiwf qrrqngqtdf frkwadyrv 1201
fgnvedfswl gldnihrts qgryelrvdm rdgqeaafas ydrfsvedsr nlyklrigsy 1261
ngtagdlsy hqgrpfsted rdndvavtnc amsykgawwy knchrtlnlg kygesrshsqg 1321
inwyhwkghe fsipfvemkm rpynhrlmag rkrqslqf

(57) Abstract: The invention provides ligands of ganglioside GD2, including peptide ligands such as GGITNYNSALM; YCG-GITNYNSACY; YCIITNYNSCY; YCGGITNYNCY; YCTNYGVHCY; YCTNYGVVCY; GGIANYNTS; YCGGIANYNCY; YCG-GIANYNTSCY; and, YCIANYNTCY. GD2 ligands of the invention may for example be used to treat or diagnose diseases such as cancers in which cells express GD2, including neuroblastomas.